Intellia Therapeutics
NTLA
10.00
+0.48
+5.04%
Intellia Therapeutics
US · NTLA
#2899 by market cap
Listed 2016
10.00
+0.48
+5.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $27Market Newswire · 2026/11/7
-
Company notice
Intellia Therapeutics | 8-K: Current reportSEC · 2026/11/13
-
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $16Market Newswire · 2026/11/14
-
Rating change
Wells Fargo Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)TipRanks · 2026/10/5
-
Rating change
Barclays Initiates Coverage On Intellia Therapeutics With Underweight Rating, Announces Price Target of $8Benzinga · 2026/10/6
-
H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/11/13
-
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49Market Newswire · 2026/11/9
-
Rating change
Wells Fargo Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $15Market Newswire · 2026/10/15
-
Company notice
Intellia Therapeutics | 8-K: Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesSEC · 2026/11/5
-
Company notice
Intellia Therapeutics | 8-K/A: Current report (Amendment)SEC · 2026/11/14
-
J.P. Morgan Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Raises Target Price to $9Market Newswire · 2026/11/9
-
Rating change
Intellia Therapeutics Price Target Announced at $8.00/Share by BarclaysDow Jones · 2026/10/7
-
Company notice
Intellia Therapeutics | 10-Q: Quarterly reportSEC · 2026/11/6
-
Rating change
Wells Fargo Keeps Their Hold Rating on Intellia Therapeutics (NTLA)TipRanks · 2026/10/15
-
Rating change
Intellia Therapeutics Initiated at Underweight by BarclaysDow Jones · 2026/10/6
-
Rating change
Barclays Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $8Market Newswire · 2026/10/7
-
Rating change
Barclays Initiates Intellia Therapeutics(NTLA.US) With Sell Rating, Announces Target Price $8Market Newswire · 2026/10/6
-
Rating change
Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13Market Newswire · 2026/9/9
-
Company notice
Intellia Therapeutics | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Rating change
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price TargetMT Newswires · 2026/10/6
-
Rating change
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price TargetBenzinga · 2026/9/9
-
Rating change
H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/9/9
-
Company notice
Intellia Therapeutics | 8-K: Current reportSEC · 2026/9/9
-
Company notice
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/10/6
-
Company notice
Intellia Therapeutics | 3: Initial statement of beneficial ownership of securities- Marantz Jing L.SEC · 2026/10/29
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.
Intellia Therapeutics discussion 0 comments